p.145 抽出テキスト

422. Goode SD, Cleveland TJ, Gaines PA. STAG trial collaborators. Randomized clinical trial of stents versus angioplasty for the treatment of iliac artery occlusions (STAG trial). Br J Surg 2013; 100: 1148-1153. PMID: 23842828 423. Grimme FA, Goverde PC, Verbruggen PJ, et al. Editor’s Choice - First Results of the Covered Endovascular Reconstruction of the Aortic Bifurcation (CERAB) Technique for Aortoiliac Occlusive Disease. Eur J Vasc Endovasc Surg 2015; 50: 638-647. PMID: 26343310 424. Indes JE, Pfaff MJ, Farrokhyar F, et al. Clinical outcomes of 5358 patients undergoing direct open bypass or endovascular treatment for aortoiliac occlusive disease: A systematic review and meta-analysis. J Endovasc Ther 2013; 20: 443-455. PMID: 23914850 425. de Vries SO, Hunink MG. Results of aortic bifurcation grafts for aortoiliac occlusive disease: A meta-analysis. J Vasc Surg 1997; 26: 558-569. PMID: 9357455 426. Ballotta E, Lorenzetti R, Piatto G, et al. Reconstructive surgery for complex aortoiliac occlusive disease in young adults. J Vasc Surg 2012; 56: 1606-1614. PMID: 23092642 427. Ricco JB, Probst H. French University Surgeons Association. Longterm results of a multicenter randomized study on direct versus crossover bypass for unilateral iliac artery occlusive disease. J Vasc Surg 2008; 47: 45-54. PMID: 17997269 428. Mohan CR, Sharp WJ, Hoballah JJ, et al. A comparative evaluation of externally supported polytetrafluoroethylene axillobifemoral and axillounifemoral bypass grafts. J Vasc Surg 1995; 21: 801-809. PMID: 7769738 429. Soga Y, Iida O, Kawasaki D, et al. REAL-AI investigators. Contemporary outcomes after endovascular treatment for aorto-iliac artery disease. Circ J 2012; 76: 2697-2704. PMID: 22864278 430. Yamauchi Y, Takahara M, Shintani Y, et al. OMOTENASHI investigators. One-Year Outcomes of Endovascular Therapy for Aortoiliac Lesions. Circ Cardiovasc Interv 2019; 12: e007441. PMID: 30616363 431. Yamauchi Y, Takahara M, Shintani Y, et al. Three-Year Outcomes of Endovascular Therapy for Aortoiliac Lesions. Circ Cardiovasc Interv 2020; 13: e009168. PMID: 32755323 432. Piazza M, Ricotta JJ 2nd, Bower TC, et al. Iliac artery stenting combined with open femoral endarterectomy is as effective as open surgical reconstruction for severe iliac and common femoral occlusive disease. J Vasc Surg 2011; 54: 402-411. PMID: 21531527 433. Chiu KW, Davies RS, Nightingale PG, et al. Review of direct anatomical open surgical management of atherosclerotic aorto-iliac occlusive disease. Eur J Vasc Endovasc Surg 2010; 39: 460-471. PMID: 20303805 434. Bredahl K, Jensen LP, Schroeder TV, et al. Mortality and complications after aortic bifurcated bypass procedures for chronic aortoiliac occlusive disease. J Vasc Surg 2015; 62: 75-82. PMID: 26115920 435. Morisaki K, Yamaoka T, Iwasa K, et al. Outcomes of endovascular therapy for infrarenal aortic occlusion of TASC II D classification Ann Vasc Surg 2017; 43: 203-209. PMID: 28302474 436. Nanto K, Iida O, Fujihara M, et al. Five-year patency and its predictors after endovascular therapy for aortoiliac occlusive disease. J Atheroscler Thromb 2019; 26: 989-996. PMID: 30996200 437. Kang JL, Patel VI, Conrad MF, et al. Common femoral artery occlusive disease: Contemporary results following surgical endarterectomy. J Vasc Surg 2008; 48: 872-877. PMID: 18639427 438. Ballotta E, Gruppo M, Mazzalai F, et al. Common femoral artery endarterectomy for occlusive disease: An 8-year single-center prospective study. Surgery 2010; 147: 268-274. PMID: 19828166 439. Chang RW, Goodney PP, Baek JH, et al. Long-term results of combined common femoral endarterectomy and iliac stenting/stent grafting for occlusive disease. J Vasc Surg 2008; 48: 362-367. PMID: 18572359 440. Changal KH, Syed MA, Dar T, et al. Systematic Review and Proportional Meta-Analysis of Endarterectomy and Endovascular Therapy with Routine or Selective Stenting for Common Femoral Artery Atherosclerotic Disease. J Interv Cardiol 2019; 2019: 1593401. PMID: 31772513 441. Gouëffic Y, Della Schiava N, Thaveau F, et al. Stenting or Surgery for De Novo Common Femoral Artery Stenosis. JACC Cardiovasc Interv 2017; 10: 1344-1354. PMID: 28683941 442. Soga Y, Tomoi Y, Sato K, et al. Clinical outcome after endovascular treatment for isolated common femoral and popliteal artery disease. Cardiovasc Interv Ther 2013; 28: 250-257. PMID: 23361951 443. Kuma S, Tanaka K, Ohmine T, et al. Clinical Outcome of Surgical Endarterectomy for Common Femoral Artery Occlusive Disease. Circ J 2016; 80: 964-969. PMID: 26902450 444. Lammer J, Zeller T, Hausegger KA, et al. Heparin-bonded covered

stents versus bare-metal stents for complex femoropopliteal artery lesions: The randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease). J Am Coll Cardiol 2013; 62: 1320-1327. PMID: 23831445 445. Scheinert D, Werner M, Scheinert S, et al. Treatment of complex

atherosclerotic popliteal artery disease with a new self-expanding interwoven nitinol stent: 12-month results of the Leipzig SUPERA popliteal artery stent registry. JACC Cardiovasc Interv 2013; 6: 65- 71. PMID: 23347863 446. Tepe G, Micari A, Keirse K, et al. IN.PACT Global Study Investigators. Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The Chronic Total Occlusion Cohort in the IN.PACT Global Study. JACC Cardiovasc Interv 2019; 12: 484-493. PMID: 30846089 447. Brodmann M, Keirse K, Scheinert D, et al. IN.PACT Global Study Investigators. Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The IN.PACT Global Study De Novo In-Stent Restenosis Imaging Cohort. JACC Cardiovasc Interv 2017; 10: 2113- 2123. PMID: 29050631 448. Tosaka A, Soga Y, Iida O, et al. Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol 2012; 59: 16-23. PMID: 22192663 449. Klinkert P, Schepers A, Burger DH, et al. Vein versus polytetrafluoroethylene in above-knee femoropopliteal bypass grafting: Fiveyear results of a randomized controlled trial. J Vasc Surg 2003; 37: 149-155. PMID: 12514593 450. Klinkert P, Post PN, Breslau PJ, et al. Saphenous vein versus PTFE for above-knee femoropopliteal bypass. A review of the literature. Eur J Vasc Endovasc Surg 2004; 27: 357-362. PMID: 15015183 451. Pereira CE, Albers M, Romiti M, et al. Meta-analysis of femoropopliteal bypass grafts for lower extremity arterial insufficiency. J Vasc Surg 2006; 44: 510-517. PMID: 16950427 452. Piffaretti G, Dorigo W, Ottavi P, et al. PROPATEN Italian Registry Group. Results of infrainguinal revascularization with bypass surgery using a heparin-bonded graft for disabling intermittent claudication due to femoropopliteal occlusive disease. J Vasc Surg 2019; 70: 166-174. PMID: 31113719 453. Humbarger O, Siracuse JJ, Rybin D, et al. Broad variation in prosthetic conduit use for femoral-popliteal bypass is not justified on the basis of contemporary outcomes favoring autologous great saphenous vein. J Vasc Surg 2019; 70: 1514-1523. PMID: 31147137 454. Iida O, Takahara M, Soga Y, et al. One-Year Outcomes of Heparin-Bonded Stent-Graft Therapy for Real-World Femoropopliteal Lesions and the Association of Patency With the Prothrombotic State Based on the Prospective, Observational, Multicenter Viabahn Stent-Graft Placement for Femoropopliteal Diseases Requiring Endovascular Therapy (VANQUISH) Study. J Endovasc Ther 2021; 28: 123-131. PMID: 32959718 455. Ishihara T, Takahara M, Iida O, et al. ZEPHYR Investigators. Comparable 2-Year Restenosis Rates Following Subintimal and Intraluminal Drug-Eluting Stent Implantation for Femoropopliteal Chronic Total Occlusion. J Endovasc Ther 2016; 23: 889-895. PMID: 27566704 456. Samson RH, Morales R, Showalter DP, et al. Heparin-bonded expanded polytetrafluoroethylene femoropopliteal bypass grafts outperform expanded polytetrafluoroethylene grafts without heparin in a long-term comparison. J Vasc Surg 2016; 64: 638-647. PMID: 27139782 457. Ohki T, Kichikawa K, Yokoi H, et al. Outcomes of the Japanese multicenter Viabahn trial of endovascular stent grafting for superficial femoral artery lesions. J Vasc Surg 2017; 66: 130-142. PMID: 28400218 458. Saxon RR, Chervu A, Jones PA, et al. Heparin-bonded, expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease: 1-year results of the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) trial. J Vasc Interv Radiol 2013; 24: 165-173. PMID: 23369553 459. Dake MD, Ansel GM, Jaff MR, et al. Zilver PTX Investigators. Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial. Circulation 2016; 133: 1472-83; discussion 1483. PMID: 26969758 460. Müller-Hülsbeck S, Benko A, Soga Y, et al. Two-Year Efficacy and Safety Results from the IMPERIAL Randomized Study of the Eluvia Polymer-Coated Drug-Eluting Stent and the Zilver PTX Polymer-free Drug-Coated Stent. Cardiovasc Intervent Radiol 2021; 44: 368-375. PMID: 33225377 461. Soga Y, Fujihara M, Iida O, et al. Japanese Patients Treated in the